Free Newsletters - Space - Defense - Environment - Energy - Solar - Nuclear
by Staff Writers
Washington (AFP) July 26, 2012
Three studies presented Thursday at a major world conference on AIDS show new ways that scientists are striving toward a cure for the three-decade-old disease.
One study focused on a group of 12 patients in France who began treatment on antiretroviral drugs within 10 weeks of becoming infected with human immunodeficiency virus, but then stopped the therapy.
The HIV virus stayed away for a median of six years in the group, known as the Visconti Cohort, which stands for "Virological and Immunological Studies in CONtrollers after Treatment Interruption."
This unique group of people did not completely eliminate HIV, but continued to possess it at an extremely low level in their cells and did not become sick.
"These results suggest that the antiretroviral treatment should be started very early after infection," said Charline Bacchus, lead researcher of the study at France's national AIDS research agency ANRS.
"Six years after interruption of treatment, patients treated early on in the post-infection period present a perfect ability to control the HIV infection."
Scientists are continuing to study the immune characteristics of this group for clues as to why they do not need prolonged medication. For most HIV patients, antiretroviral drugs must be taken for life.
There are currently 34 million people living with HIV worldwide. In the needy nations, the most affected by the pandemic, about eight million people are now taking antiretrovirals for treatment, about half those in need.
The second study involved two HIV-positive men whose DNA showed no trace of the virus eight and 17 months respectively after receiving stem cell transplants from an outside donor as treatment for blood cancer.
Their cases are unlike the well-known "Berlin patient," an American man who is considered cured of HIV and leukemia after receiving similar bone marrow transplants from a rare donor who was naturally resistant to HIV, or who lacked a CCR5 receptor.
These two men received transplants from donors with the CCR5 receptor, which acts as a gateway allowing HIV to penetrate the cells, so they were not afforded natural protection against the virus.
Researchers believe that by continuing to treat the men with antiretroviral drugs during the process, the medicine prevented the donor cells from becoming infected until they were able to provide the men with new immune defenses.
The study was presented at the 19th International AIDS Conference by Daniel Kuritzkes, professor of medicine at Brigham and Women's Hospital in Massachusetts.
A third study on how a cancer drug helped purge HIV from the cells of patients was described by lead researcher David Margolis of the University of North Carolina.
Researchers used the chemotherapy drug vorinostat to revive and so unmask latent HIV in the CD4+ T cells of eight trial patients who were also taking antiretroviral drugs to stop the virus from multiplying.
Margolis, whose study was published Wednesday in the British journal Nature, told reporters that researchers are energized toward the goal of finding a cure for HIV, even if it remains many years away.
"You cannot argue with the value of the goal and we cannot get there without working on it and I cannot say how long it will take," he said.
"But I think there is a clear path and we can make progress."
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola
|The content herein, unless otherwise known to be public domain, are Copyright 1995-2014 - Space Media Network. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement,agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. Privacy Statement|